Experimental and clinical research of HIV-1 resistance in three AIDS patients who had experienced multiple regimens

Chinese Medical Journal

Volumn 122, Issue 6, 2009, Pages 752-754

  Lu, Jun Feng ^a   Li, Jue ^b   Li, Han Ping ^b   Liu, Si Yang ^a   Zhuang, Dao Ming ^b   Liu, Yong Jian ^b   Bao, Zuo Yi ^b   Li, Lin ^b   Wu, Hao ^a   Li, Jing Yun ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Genotypic resistance; Human immunodeficiency virus type 1; Multi drug resistance; Phenotypic resistance

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; MALE; NONHUMAN; OPPORTUNISTIC INFECTION; PARESTHESIA; PATIENT COMPLIANCE; PRURITUS; VIRUS LOAD; DRUG EFFECT; METABOLISM; PHYSIOLOGY; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV-1; HUMANS; MALE;

EID: 67649807501     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.06.031     Document Type: Article

References (13)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
2. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JQ. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7: 1016-1020.
3. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41-48.
4. Zhang FJ, Maria A, Haberer J, Zhao Y. Overview of HIV drug resistance and its implications for China. Chin Med J 2006; 119: 1999-2004.
5. Luber AD. Genetic barriers to resistance and impact on clinical response. Med Gen Med 2005; 7: 69.
6. Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P, et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 2001; 309: 437-445.
7. Balzarini J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol 1999; 58: 1-27.
8. Boden D, Hurley A, Zhang L, Guo Y, Jones E, Tsay J, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282: 1135-1141.
9. Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282: 1142-1149.
10. Sen S, Tripathy SP, Paranjape RS. Antiretroviral drug resistance testing. J Postgrad Med 2006; 52: 187-193.
11. Beerenwinkel N, Daumer M, Oette M, Korn K, Hoffmann D, Kaiser R, et al. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003; 31: 3850-3855.
12. Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF, et al. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J Infect Dis 2000; 182: 59-67.
13. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lenqauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci U S A 2002; 99: 8271-8276.